How should a pregnant patient with an elevated PT/INR be managed?

Management of Elevated PT/INR in Pregnancy

The management of elevated PT/INR in pregnancy depends entirely on the underlying cause: if the patient is on warfarin anticoagulation (e.g., for mechanical heart valves), immediate reversal with vitamin K and fresh frozen plasma followed by cesarean delivery is required to prevent fetal intracranial hemorrhage; if due to intrahepatic cholestasis of pregnancy (ICP), vitamin K supplementation is indicated; and if discovered incidentally, urgent investigation for coagulopathy, liver disease, or inherited factor deficiencies is essential. 1

Warfarin-Related Elevated PT/INR

Emergency Management

• If a pregnant woman on warfarin presents in labor with elevated PT/INR, immediate reversal of anticoagulation followed by cesarean section is mandatory to prevent fetal intracranial hemorrhage. 1
• Warfarin crosses the placental barrier and anticoagulates the fetus, creating extremely high risk of fetal intracranial bleeding during vaginal delivery. 1
• Administer vitamin K and fresh frozen plasma for rapid INR reversal before delivery. 1

Planned Delivery Approach

• For planned delivery in women on warfarin, discontinue warfarin and transition to intravenous unfractionated heparin (UFH) with aPTT >2 times control at least 6 weeks before expected delivery date. 1
• Stop IV heparin at least 6 hours before delivery to reduce maternal bleeding risk and allow safe epidural placement. 1
• Coordinate exact timing with obstetrics and anesthesia teams. 1

Prevention Strategy

• Women requiring warfarin doses >5 mg/day should switch to dose-adjusted LMWH during the first trimester, then resume warfarin for second and third trimesters, with transition back to heparin at 36 weeks. 1
• Women requiring ≤5 mg/day warfarin may continue throughout pregnancy with lower embryopathy risk (<3%), though this remains controversial. 1

Intrahepatic Cholestasis of Pregnancy (ICP)

Vitamin K Deficiency Recognition

• ICP can cause severe vitamin K deficiency leading to dangerous coagulopathy with PT >100 seconds and INR >10. 2
• Cholestyramine used for refractory pruritus in ICP exacerbates vitamin K deficiency, especially at high doses. 1
• Monitor PT/INR in all women with ICP and treat with vitamin K if elevated. 1

Treatment Protocol

• Administer intramuscular vitamin K for severe coagulopathy (INR >10). 2
• Consider fresh frozen plasma for active bleeding or imminent delivery. 2
• Oral vitamin K 1-2.5 mg can reduce INR from 5.0-9.0 to 2.0-5.0 within 24-48 hours; use 5 mg for INR >10. 3
• Oral administration is preferred over IV (anaphylactoid risk) or subcutaneous (cutaneous reactions). 3

Fetal Considerations

• Newborns of mothers with ICP and coagulopathy require immediate vitamin K administration at delivery, as they remain at high risk for intracranial hemorrhage despite prophylaxis. 2
• Maternal and fetal bile acid levels correlate, supporting causal relationship between maternal coagulopathy and fetal complications. 1

Incidental Discovery of Elevated PT/INR

Diagnostic Workup

• Investigate for inherited factor deficiencies (e.g., Factor VII deficiency), which can paradoxically present with thrombotic tendency despite elevated INR. 4
• Check liver function tests and assess for underlying liver disease or cholestasis. 2, 4
• Screen for antiphospholipid antibodies if history of recurrent pregnancy loss or thrombosis. 4
• Measure vitamin K levels if cholestasis or malabsorption suspected. 2

Management Approach

• Do not assume elevated INR always indicates bleeding risk—some inherited deficiencies cause thrombophilia despite high INR. 4
• Assemble multidisciplinary team including high-risk obstetrics, hematology, and anesthesiology for delivery planning. 4
• Avoid empiric vitamin K if inherited factor deficiency suspected until diagnosis confirmed. 4

Anticoagulation for VTE in Pregnancy

Acute VTE Treatment

• Use LMWH rather than UFH for treatment of acute VTE in pregnancy. 1
• Continue anticoagulation for at least 6 weeks postpartum (minimum total duration 3 months). 1
• For planned delivery on LMWH, discontinue at least 24 hours before induction or cesarean section to allow safe neuraxial anesthesia. 1

Monitoring Requirements

• LMWH requires meticulous anti-Xa monitoring with target 0.8-1.2 U/mL at 4-6 hours post-dose, given at least twice daily. 1
• Fixed LMWH dosing without anti-Xa monitoring is associated with high maternal morbidity and mortality. 1
• Never use LMWH in pregnant women with mechanical heart valves unless anti-Xa levels are monitored. 1

Common Pitfalls

• Do not perform vaginal delivery in women anticoagulated with warfarin—this causes fetal intracranial hemorrhage. 1
• Subcutaneous UFH is inadequate for mechanical valve patients and causes prohibitive valve thrombosis rates. 1
• UFH during second and third trimesters in mechanical valve patients causes very high rates of valve thrombosis, stroke, and death. 1
• Cholestyramine for ICP pruritus worsens vitamin K deficiency—monitor PT/INR closely. 1
• Elevated INR does not always indicate bleeding risk; consider thrombophilic inherited deficiencies. 4